Rheumatology Advance Access published online on May 11, 2005
Rheumatology, doi:10.1093/rheumatology/keh672
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Rheumatology, University of Szeged, Szeged, Hungary
* To whom correspondence should be addressed. Objectives. The authors have previously identified a peptide of the human muscarinic acetylcholine receptor-3 (m3AChR) as a suitable antigen for the immunodetection of antimuscarinic acetylcholine receptor autoantibodies in primary Sjögren's syndrome (pSS). The aim of this study was to assess the clinical correlations and disease specificity of these antibodies. Methods. Seventy-three pSS, 40 rheumatoid arthritis (RA), 19 systemic lupus erythematosus (SLE), 14 secondary Sjögren's syndrome (sSS) patients, 22 subjects in whom pSS was suspected but in whom the diagnosis not could eventually be established (suspSS) and 40 healthy subjects were investigated. An enzyme-linked immunosorbent assay system developed by the authors using a 16-mer peptide of the m3AChR (m3AChR213-228) in a recombinant fusion peptide form was used as the antigen. Results. Anti-m3AChR213-228 antibody positivity was observed in 66 (90%) of the pSS patients. The antibody levels correlated positively with the number of extraglandular organ manifestations. Both the mean antibody levels and the occurrence of anti-m3AChR213-228 positivity were significantly higher in pSS than in the comparison groups. The test discriminated the pSS patients from the various comparison groups with specificities of 65, 68, 71 and 50% for RA, SLE, sSS and suspSS, respectively. Conclusions. The presence of m3AChR213-228 antibodies is a common feature in pSS. Although it is significantly more common in pSS than in the comparison groups, anti-m3AChR213-228 positivity is not exclusive to pSS.
Received December 21, 2004
Accepted April 1, 2005
Original Papers
Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3213-228 in primary Sjögren's syndrome
2 Department of Physiology, University of Szeged, Szeged, Hungary
3 Bay Zoltán Foundation for Applied Research, Institute for Biotechnology, Szeged, Hungary
4 Department of Medical Chemistry, University of Szeged, Szeged, Hungary
5 Hungarian Academy of Sciences, Clinical Neuroscience Research Group, Pécs, Hungary
L. Kovács, E-mail: kovl{at}in1st.szote.u-szeged.hu
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y Kawaguchi, Y Nakamura, I Matsumoto, E Nishimagi, T Satoh, M Kuwana, T Sumida, and M Hara Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility Ann Rheum Dis, May 1, 2009; 68(5): 710 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.-Y. Koo, J. Li, S.-M. Hwang, S.-Y. Choi, S. J. Lee, S.-B. Oh, J.-S. Kim, E. B. Lee, Y. W. Song, and K. Park Functional epitope of muscarinic type 3 receptor which interacts with autoantibodies from Sjogren's syndrome patients Rheumatology, June 1, 2008; 47(6): 828 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Reina, B. Orman, J.M. Anaya, L. Sterin-Borda, and E. Borda Cholinoreceptor Autoantibodies in Sjogren Syndrome Journal of Dental Research, September 1, 2007; 86(9): 832 - 836. [Abstract] [Full Text] [PDF]
|
|